2017
DOI: 10.1111/bjh.14524
|View full text |Cite
|
Sign up to set email alerts
|

How I manage patients with hairy cell leukaemia

Abstract: Patients with hairy cell leukaemia (HCL) have highly favourable outcomes after purine analogue therapy. However, most patients subsequently relapse and require re-treatment. A minority of patients develop purine analogue-refractory disease. Targeted therapies have improved outcomes for such patients. Recently, the BRAF V600E mutation was identified in most patients with classical HCL, resulting in constitutive mitogen-activated protein kinase pathway activation; impressive responses are achieved in heavily pre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
32
2
1

Year Published

2017
2017
2021
2021

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 32 publications
(36 citation statements)
references
References 94 publications
1
32
2
1
Order By: Relevance
“…Patients with hairy cell leukemia (HCL), a rare B cell malignancy characterized by high CD22 expression, typically present with pancytopenia and increased susceptibility to infection [ 1 ]. Although many patients achieve long-term complete remission with the purine nucleoside analogs pentostatin or cladribine [ 2 4 ], ~50% will relapse by 16 years and require additional treatment [ 5 ]. In later lines, purine nucleoside analogs offer lower complete response rate, shorter duration of response, and higher risk of cumulative toxicity compared with earlier treatment [ 5 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…Patients with hairy cell leukemia (HCL), a rare B cell malignancy characterized by high CD22 expression, typically present with pancytopenia and increased susceptibility to infection [ 1 ]. Although many patients achieve long-term complete remission with the purine nucleoside analogs pentostatin or cladribine [ 2 4 ], ~50% will relapse by 16 years and require additional treatment [ 5 ]. In later lines, purine nucleoside analogs offer lower complete response rate, shorter duration of response, and higher risk of cumulative toxicity compared with earlier treatment [ 5 7 ].…”
Section: Introductionmentioning
confidence: 99%
“…In general, the recommendation is to consider MGFs on a case-by-case basis in patients with active infections. 57,58 However, the rate of neutropenia is high, ranging from 30% to 50%, 59 which meets the threshold for recommended use of growth factors in the NCCN Guidelines for MGFs. These guidelines suggest the use of growth factors for regimens that are associated with a high risk of febrile neutropenia (>20%) or an with intermediate risk (10%-20%) in patients who have additional risk factors, such as age >65 years, hepatic or renal dysfunction, prior chemoradiotherapy, tumor involvement of the bone marrow, or recent surgery.…”
Section: Hairy Cell Leukemiamentioning
confidence: 99%
“…Diğer bir pürin analogu olan 2-Deoxycoformycin (pentostatin) ile de benzer sonuçlar bildirilmiştir (7). Bu iki ajan arasında çapraz rezistans yoktur.…”
Section: Bulgularunclassified